KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $522.0 million.

  • Supernus Pharmaceuticals' Retained Earnings fell 353.3% to $522.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $522.0 million, marking a year-over-year decrease of 353.3%. This contributed to the annual value of $556.4 million for FY2024, which is 1530.69% up from last year.
  • Supernus Pharmaceuticals' Retained Earnings amounted to $522.0 million in Q3 2025, which was down 353.3% from $567.1 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Retained Earnings' 5-year high stood at $567.1 million during Q2 2025, with a 5-year trough of $332.2 million in Q1 2021.
  • Moreover, its 5-year median value for Retained Earnings was $482.6 million (2023), whereas its average is $471.5 million.
  • In the last 5 years, Supernus Pharmaceuticals' Retained Earnings soared by 5026.82% in 2021 and then plummeted by 353.3% in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Retained Earnings (Quarter) stood at $379.9 million in 2021, then increased by 26.67% to $481.2 million in 2022, then grew by 0.27% to $482.6 million in 2023, then increased by 15.31% to $556.4 million in 2024, then dropped by 6.19% to $522.0 million in 2025.
  • Its Retained Earnings stands at $522.0 million for Q3 2025, versus $567.1 million for Q2 2025 and $544.6 million for Q1 2025.